A new map of meningioma cell surfaces finds no safe target yet
Original title: An integrative meningioma surfaceome atlas and a transferable framework for CAR-T target nomination.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was computer work on gene data, not a test in people.
The short version
Scientists looked for a good target on meningioma cells to aim an immune therapy at, and did not find one.
What was studied. Researchers studied gene activity in tumor cells from eight people with meningioma. They checked 80,220 cells to find proteins sitting on the outside of the cells.
What they found. They started with 83 possible proteins and narrowed the list to 13 true surface proteins. None of those 13 passed their safety and coverage tests. One protein called LIFR was the only one worth a closer look, and even it did not look safe enough.
What this means, and what it doesn't
What it could mean: For patients, this does not change care right now. It gives scientists a map and a method to help them search for better targets later.
What it doesn't mean: This is early lab and computer work on gene data. Nothing here was tested in people or in animals. There is no new treatment, and this is not a cure. Any therapy from this work would be many years away, if it happens at all.
Source: PubMed, October 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.